Last Updated on October 15, 2024 by The Health Master
USFDA Approval
USFDA Approval: The pharmaceutical landscape is witnessing a groundbreaking development as Lupin Limited, a global pharma major based in Mumbai, India, proudly announces the United States Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Ganirelix Acetate injection.
This 250 mcg/0.5 mL single-dose prefilled syringe marks Lupin’s foray into peptide-based injectables, reaffirming its dedication to pioneering healthcare solutions.
Understanding Ganirelix Acetate Injection
Ganirelix Acetate injection plays a crucial role in inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
This medical breakthrough addresses a significant aspect of women’s health, underlining the importance of Lupin’s innovative strides in pharmaceuticals.
Use of Ganirelix Acetate injection
Ganirelix Acetate injection is indicated for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
The Significance of USFDA Approval
Receiving USFDA approval is a monumental achievement for Lupin Limited.
It not only validates the safety and efficacy of Ganirelix Acetate but also opens doors to a broader market, allowing Lupin to offer a generic equivalent to the reference listed drug (RLD) of Organon USA LLC.
This strategic move positions Lupin as a key player in the pharmaceutical industry.
Medical Indication and Market Potential
Ganirelix Acetate injection’s indication for inhibiting premature LH surges addresses a critical aspect of reproductive health.
With an estimated annual sales figure of USD 84 million in the US, according to IQVIA MAT September 2023, the market potential for this groundbreaking pharmaceutical product is substantial.
Ganirelix as Lupin’s First Peptide-Based Injectable
The approval of Ganirelix Acetate holds special significance as it marks Lupin’s entry into the realm of peptide-based injectables.
This diversification underscores Lupin’s dynamic approach to pharmaceutical development, promising advanced solutions for various medical conditions.
Estimated Annual Sales and Lupin’s Diverse Portfolio
The projected annual sales of Ganirelix Acetate injection highlight its economic potential.
This achievement adds another feather to Lupin’s cap, complementing its extensive portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
Lupin’s Global Presence
With a presence in key regions globally, Lupin has strategically positioned itself to cater to diverse markets.
This global reach allows the company to contribute significantly to improving healthcare accessibility and affordability worldwide.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for the drug for Kidney Disease Treatment
USFDA Approval granted for this generic injection used to raise BP
USFDA Approval granted for Fluphenazine Hydrochloride Tablets
USFDA Approval granted for this Revolutionary Weight Loss Drug
USFDA Approval granted for Sitagliptin and Metformin HCL Tablets
From $50 Billion to $200 Billion: The Future Blueprint of Indian Pharma
CDSCO Guidelines on Drug Recall
Drug recall: This drug recalled due to Microbial Contamination
USFDA Inspection completed at Aurobindo Pharma Arm : Telangana
Integrating Life-Saving Medical Devices at Cricket Matches
USFDA issues warning letter to Amazon regarding Eye Drops: Read detail
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
